You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

61 Results
Guidelines and Advice
Status: Archived
ID: 21-3-6
Oct 2010
Guidelines and Advice
Status: Archived
ID: 21-3-5
Nov 2010
Guidelines and Advice
Status: Archived
ID: 21-3-4
Oct 2010
Guidelines and Advice
Status: Archived
ID: 21-3-2
Oct 2010
Guidelines and Advice
Status: Archived
ID: 21-3-10
Oct 2010
Guidelines and Advice
Status: Archived
ID: 21-3-1
Oct 2010
Guidelines and Advice
Status: Education and Information
ID: 19-3
Oct 2010
Guidelines and Advice
Status: Archived
ID: 6-21
Jan 2010
Guidelines and Advice
Status: Archived
ID: 23-1
Mar 2010
Guidelines and Advice
Status: Archived
ID: 21-1
Apr 2010
Statistical Reports
Nov 2010
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
ODB - General Benefit
    chlorambucil
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
chlorambucil,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020

Pages